亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

LBA44 Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer

医学 队列 内科学 化疗 肿瘤科 临床终点 不利影响 无进展生存期 随机对照试验
作者
Xianghua Wu,Xia Liu,Kai Zhang,Yong Tang,Guannan Zhang,De‐Shen Wang,Hanmei Lou,N. Liu,Haiyang Zhang,Huarong Chen,Kun Wang,Sen Wei,Lei Wang,Kai Gao,Guang Li,Haiyang Zhang,Yue Hu,Xianfeng Zhou,Yan Wang,Qi Wang
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1284-S1285 被引量:2
标识
DOI:10.1016/j.annonc.2023.10.038
摘要

Combining immunotherapy and anti-angiogenic agents may enhance immune response by reversing the immunosuppressive microenvironment. We conducted a randomized, open-label, phase 2 trial to assess camrelizumab (CAM, an anti-PD-1 antibody) plus famitinib (FAM, a multi-targeted TKI against VEGFR2/3) versus CAM alone and investigator’s choice of chemotherapy (chemo) for recurrent or metastatic cervical cancer (R/M CC). Patients (pts) with R/M CC who failed prior platinum-based chemo were enrolled. Prior anti-PD-1/PD-L1/CTLA-4 treatment was not allowed. Pts were randomized to receive CAM 200 mg IV Q3W with (cohort A) or without (cohort B) FAM 20 mg PO QD, or investigator’s choice of chemo (cohort C) every 3-week cycle. The primary endpoint was ORR per RECIST v1.1 assessed by blinded independent central review (BICR). At data cutoff on April 21, 2023, 194 pts were randomized (cohort A n=105, cohort B n=54, cohort C n=35), and 46 pts (23.7%) remained on treatment. 77.8% of pts had squamous CC, 63.9% were PD-L1 positive, 31.4% received prior targeted therapy. The median follow-up duration was 9.9 months (IQR 7.3-15.1). Antitumor activities are shown in the table. Treatment-related adverse events (TRAEs) occurred in 100%, 94.3%, and 100% of pts, respectively. Grade ≥3 TRAEs were reported in 84.8%, 15.1%, and 60.0% of pts, respectively, with the most common ones being decreased neutrophil count (23.8%, 1.9%, 30.0%), hypertension (22.9%, 0, 0), decreased white blood cell count (20.0%, 0, 33.3%), and anemia (20.0%, 1.9%, 13.3%). Dose discontinuation due to AEs occurred in 19.0%, 5.7%, and 0 pts, respectively. Treatment-related death was reported in two pts (1.9%) in cohort A (acute coronary syndrome, infection and sepsis).Table: LBA44Summary of efficacyCohort A (n=105)Cohort B (n=54)Cohort C (n=35)BICR-assessedCR9 (8.6)3 (5.6)—PR34 (32.4)10 (18.5)—ORR41.0 (31.5-51.0)24.1 (13.5-37.6)—DCR75.2 (65.9-83.1)55.6 (41.4-69.1)—PFS (mo)7.2 (6.1-12.4)4.0 (2.1-6.1)—Investigator-assessedCR4 (3.8)2 (3.7)1 (2.9)PR41 (39.0)10 (18.5)4 (11.4)ORR42.9 (33.2-52.9)22.2 (12.0-35.6)14.3 (4.8-30.3)DCR74.3 (64.8-82.3)53.7 (39.6-67.4)42.9 (26.3-60.7)PFS (mo)8.1 (6.2-12.4)4.1 (2.1-5.1)2.9 (2.0-6.2)12-months OS rate80.3 (70.7-87.0)71.9 (55.8-83.0)59.7 (40.9-74.3) Open table in a new tab CAM plus FAM showed improved antitumor activity than CAM alone or investigator’s choice of chemo in pts with R/M CC, with a tolerable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
9秒前
黑大侠完成签到 ,获得积分10
18秒前
20秒前
思源应助sss采纳,获得10
25秒前
量子星尘发布了新的文献求助10
27秒前
梨子茶发布了新的文献求助10
31秒前
34秒前
sss发布了新的文献求助10
40秒前
47秒前
诚心的信封完成签到 ,获得积分10
1分钟前
科研通AI5应助科研通管家采纳,获得10
1分钟前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
1分钟前
2分钟前
紫熊完成签到,获得积分10
2分钟前
2分钟前
雪流星完成签到 ,获得积分10
2分钟前
woxinyouyou完成签到,获得积分0
2分钟前
紫熊发布了新的文献求助30
2分钟前
3分钟前
3分钟前
3分钟前
量子星尘发布了新的文献求助10
3分钟前
3分钟前
4分钟前
沉沉完成签到 ,获得积分0
4分钟前
量子星尘发布了新的文献求助10
4分钟前
4分钟前
老石完成签到 ,获得积分10
4分钟前
lhn完成签到 ,获得积分10
5分钟前
P_Chem完成签到,获得积分10
5分钟前
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
5分钟前
6分钟前
量子星尘发布了新的文献求助10
6分钟前
6分钟前
7分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3960142
求助须知:如何正确求助?哪些是违规求助? 3506271
关于积分的说明 11128693
捐赠科研通 3238319
什么是DOI,文献DOI怎么找? 1789703
邀请新用户注册赠送积分活动 871870
科研通“疑难数据库(出版商)”最低求助积分说明 803069